The study, published in the Journal of Clinical Oncology, wants a policy revamp on screening guidelines for the women who fall in this category.
For the first time, a new study published in the September 2014 Journal of the National Cancer Institute (JNCI) and led by Brian Sprague, PhD, a University of Vermont (UVM) assistant professor of surgery and member of the Vermont Cancer Center, estimates the number of women in the United States for whom breast density notification legislation would potentially impact. The study was conducted with the National Breast Cancer Surveillance Consortium and utilizes data from breast cancer screening registries based at the University of Vermont, the Group Health Research Institute (Seattle, WA), the University of North Carolina, Dartmouth’s Geisel School of Medicine, the University of California-San Francisco, and the University of New Mexico.
Given their findings, Sprague and his research team are asking policy makers to consider the large number of women who fall into the category of having mammographically-dense breasts in the US as they debate breast density notification legislation and screening recommendations.
Link to the press release: http://bit.ly/YTbgSV
Source: The University of Vermont
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Trastuzumab Deruxtecan Receives FDA Approval for HER2-Positive Solid Tumors
April 5th 2024FDA granted accelerated approval to trastuzumab deruxtecan-nxki for adult patients with unresectable or metastatic HER2-positive solid tumors who received prior systemic treatment and have no satisfactory alternative treatment options.
Read More